Do analysts recommend CODX or PPCB?

Co-Diagnostics currently has a consensus target price of $67.50, indicating a potential upside of 5,769.57%. Given Co-Diagnostics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Co-Diagnostics is more favorable than Propanc Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Co-Diagnostics 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.50 Propanc Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media refer more to CODX or PPCB?

In the previous week, Co-Diagnostics had 3 more articles in the media than Propanc Biopharma. MarketBeat recorded 6 mentions for Co-Diagnostics and 3 mentions for Propanc Biopharma. Co-Diagnostics' average media sentiment score of 0.00 equaled Propanc Biopharma'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Co-Diagnostics 0 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Propanc Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer PPCB or BOLT?

Bolt Biotherapeutics has a consensus target price of $14.50, indicating a potential upside of 303.90%. Given Bolt Biotherapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Bolt Biotherapeutics is more favorable than Propanc Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Propanc Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Bolt Biotherapeutics 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Does the media prefer PPCB or BOLT?

In the previous week, Bolt Biotherapeutics had 15 more articles in the media than Propanc Biopharma. MarketBeat recorded 18 mentions for Bolt Biotherapeutics and 3 mentions for Propanc Biopharma. Propanc Biopharma's average media sentiment score of 0.00 beat Bolt Biotherapeutics' score of -0.10 indicating that Propanc Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Propanc Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Bolt Biotherapeutics 1 Very Positive mention(s) 5 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate ERNA or PPCB?

Ernexa Therapeutics presently has a consensus target price of $30.00, suggesting a potential upside of 728.73%. Given Ernexa Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Ernexa Therapeutics is more favorable than Propanc Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ernexa Therapeutics 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Propanc Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is ERNA or PPCB more profitable?

Propanc Biopharma's return on equity of -151.28% beat Ernexa Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Ernexa Therapeutics N/A -305.93% -169.86% Propanc Biopharma N/A -151.28% -109.53%

Does the media favor ERNA or PPCB?

In the previous week, Propanc Biopharma had 1 more articles in the media than Ernexa Therapeutics. MarketBeat recorded 3 mentions for Propanc Biopharma and 2 mentions for Ernexa Therapeutics. Ernexa Therapeutics' average media sentiment score of 0.29 beat Propanc Biopharma's score of 0.00 indicating that Ernexa Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ernexa Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Propanc Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer OSRH or PPCB?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score OSR 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Propanc Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is OSRH or PPCB more profitable?

Propanc Biopharma has a net margin of 0.00% compared to OSR's net margin of -593.15%. OSR's return on equity of -8.36% beat Propanc Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets OSR -593.15% -8.36% -6.24% Propanc Biopharma N/A -151.28% -109.53%

Do analysts recommend PPCB or CDIO?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Propanc Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Cardio Diagnostics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media refer more to PPCB or CDIO?

In the previous week, Propanc Biopharma and Propanc Biopharma both had 3 articles in the media. Cardio Diagnostics' average media sentiment score of 0.84 beat Propanc Biopharma's score of 0.00 indicating that Cardio Diagnostics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Propanc Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cardio Diagnostics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Propanc Biopharma (PPCB) Competitors

$0.60 -0.03 (-4.17%)

Closing price 04:00 PM Eastern

Extended Trading

$0.58 -0.02 (-3.46%)

As of 07:57 PM Eastern

Compare

PPCB vs. CODX, BOLT, ERNA, OSRH, and CDIO

Should you buy Propanc Biopharma stock or one of its competitors? Propanc Biopharma's main competitors and comparable companies include Co-Diagnostics (CODX), Bolt Biotherapeutics (BOLT), Ernexa Therapeutics (ERNA), OSR (OSRH), and Cardio Diagnostics (CDIO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Propanc Biopharma compare to Co-Diagnostics?

Co-Diagnostics (NASDAQ:CODX) and Propanc Biopharma (NASDAQ:PPCB) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, profitability, dividends, risk, earnings, institutional ownership, analyst recommendations and valuation.

Propanc Biopharma has a net margin of 0.00% compared to Co-Diagnostics' net margin of -6,531.77%. Propanc Biopharma's return on equity of -151.28% beat Co-Diagnostics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Co-Diagnostics	-6,531.77%	-210.99%	-174.97%
Propanc Biopharma	N/A	-151.28%	-109.53%

Co-Diagnostics currently has a consensus target price of $67.50, indicating a potential upside of 5,769.57%. Given Co-Diagnostics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Co-Diagnostics is more favorable than Propanc Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Co-Diagnostics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
Propanc Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Co-Diagnostics has a beta of 2.85, indicating that its stock price is 185% more volatile than the broader market. Comparatively, Propanc Biopharma has a beta of 3.52, indicating that its stock price is 252% more volatile than the broader market.

In the previous week, Co-Diagnostics had 3 more articles in the media than Propanc Biopharma. MarketBeat recorded 6 mentions for Co-Diagnostics and 3 mentions for Propanc Biopharma. Co-Diagnostics' average media sentiment score of 0.00 equaled Propanc Biopharma'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Co-Diagnostics	0 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Propanc Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

15.0% of Co-Diagnostics shares are owned by institutional investors. 2.3% of Co-Diagnostics shares are owned by insiders. Comparatively, 28.7% of Propanc Biopharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Co-Diagnostics has higher revenue and earnings than Propanc Biopharma. Co-Diagnostics is trading at a lower price-to-earnings ratio than Propanc Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Co-Diagnostics	$620K	12.95	-$46.90M	-$10.32	N/A
Propanc Biopharma	N/A	N/A	-$58.92M	-$24.25	N/A

Summary

Co-Diagnostics beats Propanc Biopharma on 9 of the 15 factors compared between the two stocks.

How does Propanc Biopharma compare to Bolt Biotherapeutics?

Propanc Biopharma (NASDAQ:PPCB) and Bolt Biotherapeutics (NASDAQ:BOLT) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, media sentiment, earnings, risk and valuation.

Propanc Biopharma has a net margin of 0.00% compared to Bolt Biotherapeutics' net margin of -611.47%. Bolt Biotherapeutics' return on equity of -126.23% beat Propanc Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Propanc Biopharma	N/A	-151.28%	-109.53%
Bolt Biotherapeutics	-611.47%	-126.23%	-54.70%

In the previous week, Bolt Biotherapeutics had 15 more articles in the media than Propanc Biopharma. MarketBeat recorded 18 mentions for Bolt Biotherapeutics and 3 mentions for Propanc Biopharma. Propanc Biopharma's average media sentiment score of 0.00 beat Bolt Biotherapeutics' score of -0.10 indicating that Propanc Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Propanc Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Bolt Biotherapeutics	1 Very Positive mention(s)	5 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

86.7% of Bolt Biotherapeutics shares are owned by institutional investors. 28.7% of Propanc Biopharma shares are owned by company insiders. Comparatively, 9.4% of Bolt Biotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Bolt Biotherapeutics has higher revenue and earnings than Propanc Biopharma. Bolt Biotherapeutics is trading at a lower price-to-earnings ratio than Propanc Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Propanc Biopharma	N/A	N/A	-$58.92M	-$24.25	N/A
Bolt Biotherapeutics	$7.70M	0.90	-$33.38M	-$16.44	N/A

Propanc Biopharma has a beta of 3.52, suggesting that its share price is 252% more volatile than the broader market. Comparatively, Bolt Biotherapeutics has a beta of 1.09, suggesting that its share price is 9% more volatile than the broader market.

Bolt Biotherapeutics has a consensus target price of $14.50, indicating a potential upside of 303.90%. Given Bolt Biotherapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Bolt Biotherapeutics is more favorable than Propanc Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Propanc Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Bolt Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Summary

Bolt Biotherapeutics beats Propanc Biopharma on 10 of the 15 factors compared between the two stocks.

How does Propanc Biopharma compare to Ernexa Therapeutics?

Ernexa Therapeutics (NASDAQ:ERNA) and Propanc Biopharma (NASDAQ:PPCB) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, analyst recommendations, earnings, profitability, media sentiment and dividends.

Ernexa Therapeutics has higher revenue and earnings than Propanc Biopharma. Ernexa Therapeutics is trading at a lower price-to-earnings ratio than Propanc Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ernexa Therapeutics	$580K	10.17	-$14.08M	-$14.35	N/A
Propanc Biopharma	N/A	N/A	-$58.92M	-$24.25	N/A

Ernexa Therapeutics presently has a consensus target price of $30.00, suggesting a potential upside of 728.73%. Given Ernexa Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Ernexa Therapeutics is more favorable than Propanc Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ernexa Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Propanc Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

70.6% of Ernexa Therapeutics shares are held by institutional investors. 0.5% of Ernexa Therapeutics shares are held by insiders. Comparatively, 28.7% of Propanc Biopharma shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Propanc Biopharma's return on equity of -151.28% beat Ernexa Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ernexa Therapeutics	N/A	-305.93%	-169.86%
Propanc Biopharma	N/A	-151.28%	-109.53%

Ernexa Therapeutics has a beta of 2.61, meaning that its stock price is 161% more volatile than the broader market. Comparatively, Propanc Biopharma has a beta of 3.52, meaning that its stock price is 252% more volatile than the broader market.

In the previous week, Propanc Biopharma had 1 more articles in the media than Ernexa Therapeutics. MarketBeat recorded 3 mentions for Propanc Biopharma and 2 mentions for Ernexa Therapeutics. Ernexa Therapeutics' average media sentiment score of 0.29 beat Propanc Biopharma's score of 0.00 indicating that Ernexa Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ernexa Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Propanc Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Ernexa Therapeutics beats Propanc Biopharma on 8 of the 14 factors compared between the two stocks.

How does Propanc Biopharma compare to OSR?

OSR (NASDAQ:OSRH) and Propanc Biopharma (NASDAQ:PPCB) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, media sentiment, profitability, valuation, risk and institutional ownership.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OSR	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Propanc Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

55.3% of OSR shares are owned by institutional investors. 36.9% of OSR shares are owned by company insiders. Comparatively, 28.7% of Propanc Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Propanc Biopharma has a net margin of 0.00% compared to OSR's net margin of -593.15%. OSR's return on equity of -8.36% beat Propanc Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OSR	-593.15%	-8.36%	-6.24%
Propanc Biopharma	N/A	-151.28%	-109.53%

In the previous week, Propanc Biopharma had 3 more articles in the media than OSR. MarketBeat recorded 3 mentions for Propanc Biopharma and 0 mentions for OSR. OSR's average media sentiment score of 0.00 equaled Propanc Biopharma'saverage media sentiment score.

Company	Overall Sentiment
OSR	Neutral
Propanc Biopharma	Neutral

OSR has higher revenue and earnings than Propanc Biopharma. OSR is trading at a lower price-to-earnings ratio than Propanc Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OSR	$1.81M	5.05	-$27.06M	-$0.37	N/A
Propanc Biopharma	N/A	N/A	-$58.92M	-$24.25	N/A

OSR has a beta of 0.49, meaning that its stock price is 51% less volatile than the broader market. Comparatively, Propanc Biopharma has a beta of 3.52, meaning that its stock price is 252% more volatile than the broader market.

Summary

OSR beats Propanc Biopharma on 7 of the 11 factors compared between the two stocks.

How does Propanc Biopharma compare to Cardio Diagnostics?

Propanc Biopharma (NASDAQ:PPCB) and Cardio Diagnostics (NASDAQ:CDIO) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, media sentiment, analyst recommendations, dividends, valuation, risk, institutional ownership and earnings.

Propanc Biopharma has a beta of 3.52, meaning that its share price is 252% more volatile than the broader market. Comparatively, Cardio Diagnostics has a beta of 2.28, meaning that its share price is 128% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Propanc Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Cardio Diagnostics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Propanc Biopharma has a net margin of 0.00% compared to Cardio Diagnostics' net margin of -43,133.33%. Cardio Diagnostics' return on equity of -82.28% beat Propanc Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Propanc Biopharma	N/A	-151.28%	-109.53%
Cardio Diagnostics	-43,133.33%	-82.28%	-76.03%

In the previous week, Propanc Biopharma and Propanc Biopharma both had 3 articles in the media. Cardio Diagnostics' average media sentiment score of 0.84 beat Propanc Biopharma's score of 0.00 indicating that Cardio Diagnostics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Propanc Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cardio Diagnostics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

8.1% of Cardio Diagnostics shares are held by institutional investors. 28.7% of Propanc Biopharma shares are held by company insiders. Comparatively, 9.0% of Cardio Diagnostics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Cardio Diagnostics has higher revenue and earnings than Propanc Biopharma. Cardio Diagnostics is trading at a lower price-to-earnings ratio than Propanc Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Propanc Biopharma	N/A	N/A	-$58.92M	-$24.25	N/A
Cardio Diagnostics	$10K	571.87	-$6.50M	-$2.92	N/A

Summary

Cardio Diagnostics beats Propanc Biopharma on 7 of the 11 factors compared between the two stocks.

Get Propanc Biopharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PPCB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PPCB vs. The Competition

Export

Metric	Propanc Biopharma	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.48M	$3.98B	$7.32B	$13.29B
Dividend Yield	N/A	3.63%	2.52%	12.57%
P/E Ratio	-0.02	14.00	274.40	25.76
Price / Sales	N/A	1,346.15	639.79	86.88
Price / Cash	N/A	113.29	77.80	52.76
Price / Book	0.02	15.46	10.52	6.34
Net Income	-$58.92M	-$22.82M	$3.49B	$360.00M
7 Day Performance	-4.48%	-2.21%	-1.08%	-0.11%
1 Month Performance	-47.90%	-6.66%	-3.39%	-3.42%
1 Year Performance	-98.76%	30.99%	15.08%	5.46%

Propanc Biopharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PPCB Propanc Biopharma	0.8359 of 5 stars	$0.60 -4.2%	N/A	-98.7%	$1.48M	N/A	N/A	2	Short Interest Decrease
CODX Co-Diagnostics	1.9266 of 5 stars	$1.11 -0.9%	$67.50 +5,981.1%	-90.8%	$7.75M	$620K	N/A	100	Gap Down
BOLT Bolt Biotherapeutics	2.428 of 5 stars	$3.96 +0.3%	$14.50 +266.1%	-34.2%	$7.65M	$7.70M	N/A	90	News Coverage Gap Down
ERNA Ernexa Therapeutics	3.2237 of 5 stars	$4.27 +2.6%	$30.00 +602.6%	-87.9%	$6.96M	$580K	N/A	10
OSRH OSR	0.2031 of 5 stars	$0.19 -7.9%	N/A	-62.5%	$6.50M	$1.81M	N/A	N/A	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PPCB) was last updated on 9/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Propanc Biopharma (PPCB) Competitors

PPCB vs. CODX, BOLT, ERNA, OSRH, and CDIO

How does Propanc Biopharma compare to Co-Diagnostics?

Summary

How does Propanc Biopharma compare to Bolt Biotherapeutics?

Summary

How does Propanc Biopharma compare to Ernexa Therapeutics?

Summary

How does Propanc Biopharma compare to OSR?

Summary

How does Propanc Biopharma compare to Cardio Diagnostics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PPCB vs. The Competition

Propanc Biopharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Propanc Biopharma (PPCB) Competitors

PPCB vs. CODX, BOLT, ERNA, OSRH, and CDIO

How does Propanc Biopharma compare to Co-Diagnostics?

Is CODX or PPCB more profitable?

Do analysts recommend CODX or PPCB?

Which has more volatility and risk, CODX or PPCB?

Does the media refer more to CODX or PPCB?

Do institutionals and insiders have more ownership in CODX or PPCB?

Which has stronger valuation & earnings, CODX or PPCB?

Summary

How does Propanc Biopharma compare to Bolt Biotherapeutics?

Is PPCB or BOLT more profitable?

Does the media prefer PPCB or BOLT?

Do institutionals and insiders believe in PPCB or BOLT?

Which has stronger earnings & valuation, PPCB or BOLT?

Which has more volatility & risk, PPCB or BOLT?

Do analysts prefer PPCB or BOLT?

Summary

How does Propanc Biopharma compare to Ernexa Therapeutics?

Which has higher earnings & valuation, ERNA or PPCB?

Do analysts rate ERNA or PPCB?

Do insiders and institutionals hold more shares of ERNA or PPCB?

Is ERNA or PPCB more profitable?

Which has more volatility & risk, ERNA or PPCB?

Does the media favor ERNA or PPCB?

Summary

How does Propanc Biopharma compare to OSR?

Do analysts prefer OSRH or PPCB?

Do insiders and institutionals have more ownership in OSRH or PPCB?

Is OSRH or PPCB more profitable?

Does the media prefer OSRH or PPCB?

Which has better valuation and earnings, OSRH or PPCB?

Which has more risk and volatility, OSRH or PPCB?

Summary

How does Propanc Biopharma compare to Cardio Diagnostics?

Which has more risk & volatility, PPCB or CDIO?

Do analysts recommend PPCB or CDIO?

Is PPCB or CDIO more profitable?

Does the media refer more to PPCB or CDIO?

Do insiders and institutionals have more ownership in PPCB or CDIO?

Which has higher valuation & earnings, PPCB or CDIO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PPCB vs. The Competition

Propanc Biopharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools